Glover A.R. Ip J.C. Zhao J.T. et al.

Current management options for recurrent adrenocortical carcinoma.

Onco Targets Ther. 2013; 6: 635-643Bianchini M. Puliani G. Chiefari A. et al.

Metabolic and endocrine toxicities of mitotane: a systematic review.

Cancers (Basel). 2021; 13: 5001Assié G. Antoni G. Tissier F. et al.

Prognostic parameters of metastatic adrenocortical carcinoma.

J Clin Endocrinol Metab. 2007; 92: 148-154Kiseljak-Vassiliades K. Bancos I. Hamrahian A. et al.

American association of clinical endocrinology disease state clinical review on the evaluation and management of adrenocortical carcinoma in an adult: a practical approach.

Endocr Pract. 2020; 26: 1366-1383Postlewait L.M. Ethun C.G. Tran T.B. et al.

Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group.

J Am Coll Surg. 2016; 222 ([published correction appears in J Am Coll Surg. 2018 Jan;226(1):114]): 480-490Terzolo M. Fassnacht M. Perotti P. et al.

Results of the ADIUVO Study, the First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients.

J Endocr Soc. 2021; 5 (Published 2021 May 3): A166-A167

Severe adrenal cortical atrophy (cytotoxic) and hepatic damage produced in dogs by feeding 2,2-bis(parachlorophenyl)-1,1-dichloroethane (DDD or TDE).

Arch Pathol (Chic). 1949; 48: 387-394Bergenstal D.M. Hertz R. Lipsett M.B. et al.

Chemotherapy of adrenocortical cancer with o,p′ddd.

Ann Intern Med. 1960; 53: 672-682Hescot S. Amazit L. Lhomme M. et al.

Identifying mitotane-induced mitochondria-associated membranes dysfunctions: metabolomic and lipidomic approaches.

Oncotarget. 2017; 8 (Published 2017 Jul 4): 109924-109940https://doi.org/10.18632/oncotarget.18968Bradlow H.L. Fukushima D.K. Zumoff B. et al.

A peripheral action of o,p' -ddd on steroid biotransformation.

J Clin Endocrinol Metab. 1963; 23: 918-922Brown R.D. Nicholson W.E. Chick W.T. et al.

Effect of o,p'DDD on human adrenal steroid 11 beta-hydroxylation activity.

J Clin Endocrinol Metab. 1973; 36: 730-733Kroiss M. Quinkler M. Lutz W.K. et al.

Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma.

Clin Endocrinol (Oxf). 2011; 75: 585-591Berruti A. Fassnacht M. Libè R. et al.

First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: the adjuvo study.

J Clin Oncol. 2022; 40: 1Paragliola R.M. Torino F. Papi G. et al.

Role of mitotane in adrenocortical carcinoma - review and state of the art.

Eur Endocrinol. 2018; 14: 62-66Tang Y. Liu Z. Zou Z. et al.

Benefits of adjuvant mitotane after resection of adrenocortical carcinoma: a systematic review and meta-analysis.

Biomed Res Int. 2018; 2018: 9362108Fassnacht M. Assie G. Baudin E. et al.

Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2020; 31: 1476-1490Karwacka I. Obołończyk Ł. Kaniuka-Jakubowska S. et al.

The Role of Immunotherapy in the Treatment of Adrenocortical Carcinoma.

Biomedicines. 2021; 9: 98Fassnacht M. Terzolo M. Allolio B. et al.

Combination chemotherapy in advanced adrenocortical carcinoma.

N Engl J Med. 2012; 366: 2189-2197Uchihara M. Tanioka M. Kojima Y. et al.

Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experience.

Int J Clin Oncol. 2021; 26: 2275-2281Berruti A. Sperone P. Ferrero A. et al.

Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma.

Eur J Endocrinol. 2012; 166: 451-458Kroiss M. Quinkler M. Johanssen S. et al.

Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial.

J Clin Endocrinol Metab. 2012; 97: 3495-3503Urup T. Pawlak W.Z. Petersen P.M. et al.

Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study.

Br J Cancer. 2013; 108: 1994-1997Naing A. Lorusso P. Fu S. et al.

Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma.

Br J Cancer. 2013; 108: 826-830O'Sullivan C. Edgerly M. Velarde M. et al.

The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer.

J Clin Endocrinol Metab. 2014; 99: 1291-1297Fassnacht M. Berruti A. Baudin E. et al.

Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study.

Lancet Oncol. 2015; 16: 426-435https://doi.org/10.1016/S1470-2045(15)70081-1Le Tourneau C. Hoimes C. Zarwan C. et al.

Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial.

J Immunother Cancer. 2018; 6: 111Habra M.A. Stephen B. Campbell M. et al.

Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma.

J Immunother Cancer. 2019; 7: 253Carneiro B.A. Konda B. Costa R.B. et al.

Nivolumab in metastatic adrenocortical carcinoma: results of a phase 2 trial.

J Clin Endocrinol Metab. 2019; 104: 6193-6200Raj N. Zheng Y. Kelly V. et al.

PD-1 blockade in advanced adrenocortical carcinoma.

J Clin Oncol. 2020; 38: 71-80Yip L. Duh Q.Y. Wachtel H. et al.

American Association of Endocrine Surgeons Guidelines for Adrenalectomy: Executive Summary.

JAMA Surg. 2022; 157: 870-877Bednarski B.K. Habra M.A. Phan A. et al.

Borderline resectable adrenal cortical carcinoma: a potential role for preoperative chemotherapy.

World J Surg. 2014; 38: 1318-1327Paragliola R.M. Corsello A. Locantore P. et al.

Medical approaches in adrenocortical carcinoma.

Biomedicines. 2020; 8: 551